T1	Participants 70 84	uveal melanoma
T2	Participants 389 403	uveal melanoma
T3	Participants 579 686	120 patients with metastatic uveal melanoma at 15 academic oncology centers in the United States and Canada
T4	Participants 702 1000	One hundred one patients were randomized in a 1:1 ratio to receive selumetinib, 75 mg orally twice daily on a continual basis (n = 50), or chemotherapy (temozolomide, 150 mg/m2 orally daily for 5 of every 28 days, or dacarbazine, 1000 mg/m2 intravenously every 21 days [investigator choice]; n = 51
T5	Participants 1123 1250	19 patients were registered and 18 treated with selumetinib without randomization to complete the planned 120-patient enrollmen
T6	Participants 2587 2624	patients with advanced uveal melanoma
